Jennifer Taubert, Worldwide Chairman, Pharmaceuticals, joined Johnson & Johnson in 2005 and is a leader in shaping Janssen Pharmaceuticals’ global strategy of transformational medical innovation, successfully commercializing critical new medicines that significantly improve the lives of patients living with cancer, immune-related diseases, heart disease and diabetes, infectious diseases, pulmonary hypertension and serious mental illness. She has built a portfolio that includes nine blockbuster therapies, and under her leadership Janssen has become one of the largest and fastest-growing pharmaceutical companies and a major catalyst of Johnson & Johnson’s growth. Jennifer is also recognized as a champion of diversity and inclusion, which she sees as critical to insight, innovation and business success. Jennifer was named to Fortune magazine’s “Most Powerful Women” list in 2016 and 2017, and received the National Association for Female Executives’ 2017 “Woman of Achievement” award. Boards & Memberships: Director: Biotechnology Innovation Organization (BIO), the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations Executive Committee Member: International Section of the Pharmaceutical Research and Manufacturers of America (PhRMA) Member: National Academy of Medicine Leadership Consortium for Value and Science-Driven Healthcare